PFBT
TRDA icon

Parkside Financial Bank & Trust’s Entrada Therapeutics TRDA Stock Holding History

Parkside Financial Bank & Trust’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40
Closed -$362 – 2994
2025
Q1 		$362 Buy
+40
New +$498 ﹤0.01% 2587

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Parkside Financial Bank & Trust's TRDA Position: Q2 2025 in Review

Parkside Financial Bank & Trust sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 40 shares — an estimated $362 sold.

Parkside Financial Bank & Trust first reported a position in TRDA in Q1 2025 and held it in 1 quarter. The position peaked at $362 in Q1 2025. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Parkside Financial Bank & Trust reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 40 Entrada Therapeutics shares in Q2 2025, an estimated $362.
  • Parkside Financial Bank & Trust first reported a position in Entrada Therapeutics in Q1 2025 and held it in 1 quarter.
  • Parkside Financial Bank & Trust's Entrada Therapeutics position peaked at $362 in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2025, filed 7 Aug 2025.